Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma - Santo, L; Hideshima, T; Kung, A L; Tseng, J C; Tamang, D; Yang, M; Jarpe, M; van Duzer, J H; Mazitschek, R; Ogier, W C; Cirstea, D; Rodig, S; Eda, H; Scullen, T; Canavese, M; Bradner, J; Anderson, K C; Jones, S S; Raje, N (Blood, 2012)